As previously reported, Raymond James upgraded RA Pharmaceuticals (RARX) to Strong Buy from Outperform with a $28 price target. Analyst Steven Seedhouse expects Phase 2 data for lead subcutaneous C5 inhibitor zilucoplan in generalized myasthenia gravis expected around YE18 to demonstrate a treatment benefit in a mixed refractory/non-refractory patient population and be competitive with Alexion's (ALXN) Soliris. Seedhouse believes a positive Phase 2 readout could be worth $1B in market cap at least and could treat a broader population of patients than Soliris given subcutaneous administration and pricing leverage.